NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief Device
September 22 2020 - 7:00AM
NeuroMetrix, Inc. (Nasdaq: NURO) today reported the launch of
the Quell Watch App, now available for download from the Apple App
store.
Quell is a wearable, transcutaneous electrical nerve stimulation
(TENS) device for knee, foot and leg pain that is available
over-the-counter. It can be used during the day while active and at
night while sleeping. Users can personalize and manage therapy
discreetly via the mobile app for iPhone and Android smartphones.
Quell is also a pain management solution with pain, sleep, activity
and gait tracking. The Quell Health Cloud® provides customized
feedback and powers one of the largest chronic pain outcomes
databases. To learn more visit www.QuellRelief.com.
Like Quell, a smartwatch is always on the body. This enables a
high level of integration and novel pain relief functionality. It
is for this reason that NeuroMetrix developed the Quell Watch app,
the first and only TENS smartwatch app. The Quell Watch app was
designed to leverage the unique features of the Apple Watch.
The Quell Watch app is standalone, so it functions independently
of the iPhone. It gives a Quell user the ability to control the
device and monitor pain relief from the wrist; a level of
convenience never before achieved with a TENS device. The user
simply taps the Quell complication to open the app. The user can
then easily start or stop therapy, increase or decrease intensity,
view their therapy schedule, and get Quell status information. The
battery level can be checked by just glancing at the
complication.
A particularly valuable feature of the Quell Watch app is
notifications. The app is in regular, behind the scenes,
communication with Quell. This enables alerts such as when the
Quell battery is low or if therapy unexpectedly halted. These
notifications help ensure that the user does not miss out on pain
relief. The notifications are configurable so the Quell Watch app
experience can be personalized.
"The promise of wearable technology is to enhance wellness and
help manage disease by empowering people to monitor and improve
their own health. Quell is the clear innovation leader in wearable
pain relief," said Shai N. Gozani, M.D., Ph.D., President and CEO
of NeuroMetrix. "The natural evolution of wearable technology is to
move beyond each device operating in isolation, to a situation
where devices interact to maximize health outcomes. The initial
release of the Quell Watch app provides a unique and differentiated
experience for Quell users managing their chronic pain. It is an
exciting and important beginning for smartwatch innovation from
NeuroMetrix."
About NeuroMetrix
NeuroMetrix is a leading developer and manufacturer of
diagnostic and therapeutic neurostimulation-based medical devices
that are used throughout the world. The Company has three FDA
cleared commercial products. DPNCheck® is a point-of-care test that
is used to evaluate peripheral neuropathies. ADVANCE™ is a
point-of-care device that provides nerve conduction studies as an
aid in diagnosing and evaluating patients suspected of having focal
or systemic neuropathies. Quell® is a wearable, mobile app enabled,
neurostimulation device indicated for symptomatic relief and
management of chronic pain and is available over-the-counter. The
Company maintains an active, industry-leading R&D program. For
more information, visit NeuroMetrix.com.
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial Officerneurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/98b63a9d-7a78-45e9-8852-350357f41c75
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Apr 2024 to May 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From May 2023 to May 2024